1 / 24

Mifepriston in emergency contraception

Mifepriston in emergency contraception. V.N.Prilepskaya , А.А. Kuzemin , Т.А. Nazarenko , Т.М. Astahova Research Centre of Obstetrics , Gynecology & Perinatology, Moscow. Main directions in the study of emergency contraception:.

dremal
Télécharger la présentation

Mifepriston in emergency contraception

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Mifepriston in emergencycontraception V.N.Prilepskaya, А.А.Kuzemin, Т.А.Nazarenko, Т.М.Astahova Research Centre of Obstetrics, Gynecology & Perinatology, Moscow

  2. Main directions in the study of emergency contraception: • Creation of the International Consortium on Emergency Contraception • Enhancement of the WHO studies on that theme • Study of efficacy and comparison of different methods (Youzpe method, levonorgestrel and mifepriston in different doses) • Prolongation of an interval after an unprotected sex (from 72 tо 120 hrs)

  3. Three regimens have been studied for emergency contraception Randomized double blind study in 15 family planning clinics in 10 countries 4136 healthy women with regular menstrual cycle). • Single dose of levonorgestrel – 1,5 мg • Two doses of levonorgestrel with an interval of 12 hrs • Single dose of Mifepriston – 10mg

  4. Conclusion • «All three regimens are very efficient for emergency contraception and prevent a high per cent of pregnancies if taken during the first 5 days» Helene von Hertzen et al. Lancet 2002, 360:1803-10

  5. Мifepriston Synthetic steroid, derivative of nortetisteron with antigestagen activity. Main indication is medical abortion Additional indications: • Treatment of uterine leyomyoma • Emergency contraception

  6. Mifepriston (tablets 10 мg, Мir-Pharm) • As a means of emergency contraception mifepriston was registered after clinical trials and was approved for clinical practice in Russia in 2004

  7. Objectives • To assess efficacy and safety of low-dose mifepristone(10мг) as a method of emergency contraception

  8. Clinical Trials • Clinical trials on these indications were carried out for the first time at the Research center of Obstetrics, Gynecology & Perinatology of the Russian Academy of Medical Sciences, Russia • Coordinator of the trial - Member of the Academy of the Medical Sciences Vladimir I. Kulakov • A total of 30 women were included in this trial

  9. Inclusion criteria: • Unprotected sex not more than 72 hrs tо visit • Reproductive age • Regular menstrual cycle during the last three months • No of psychic pathology • Patient informed consent

  10. Exclusion criteria: • Using of other contraceptive methods • Postpartum period • Adrenal insufficiency • Thromboses in the medical/family history • Severe diabetes mellitus • Genital tumor

  11. Indications for emergency contraception • Absence of any contraception in regular sexual life (25) • Failure of condom (2) • IUD expulsion during the cycle of the study (2) • Sexual abuse (1) • Age from 18 to 33 years, mean age 23,8+/-1,7 years

  12. Methods of study • Clinical (medical history, examinations etc.) • Questionnaire • Blood/urine tests, biochemical tests • Bacterioscopy of vaginal discharge • Tests for genital infections, HIV • Sonography of pelvis organs with Doppler modes • HCG test in blood • Progesterone test in blood

  13. Study design included four visits: • Screening • 7-8th days after the intended menstrual period • 7-8 th days of the following menstrual period • Two months later the 3-rdvisit

  14. Parameters of efficiency • No pregnancies А) verified by sonography В) verified by HCG Basic criteria - a number of pregnancies/ number of women using Mifepriston

  15. FINDINGS:

  16. No pregnanciesin 30 patients

  17. Results: • Side effects: long (in average up to 46 days) or postponed cycles - 34-36 days - in 5 (16%) patients on 2 – 3 visits • Cycle was regular in all patients - by the 4 visit • None of any other side effects

  18. By the 4th visit all 300 patients had regular cycles 40-46 34-36 28-30 28-30 Namber of days

  19. Remote results of examination (2-3 months after the 3 visit) • Regular menstrual cycle was in all patients • Mean duration of mensyrual cycle of 28,1+/-3,2 days • Mean duration of menstruation 5,4+/-0,7

  20. Conclusion Results of the study testify of the following: • High efficacy of Mifepriston in a single dose taken during 72 hrs as a method of emergency contraception • Its good tolerance • Normalizations of cycles in due time

  21. Conclusion • «Mifepriston delayed ovulation that means prolonged cycle and delayed of following menstrual cycle»

  22. Drawbacks: • Small number of cases • No of control group

  23. Further investigations • Comparison of Mifepriston effect in the dose of 10 мgin different regimens of use: 72 and 120 hrs after unprotected sex Intended design: 150 patients in each group

  24. Thank you for your attention

More Related